Ab­b­Vie’s next CEO; $100B club re­fresh; Top 100 VCs, 2023; More hope for CAR-T in au­toim­mune; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Is this the big turn­around year for biotech in­vest­ment? If you missed John Car­roll’s pan­el dis­cus­sion on the top­ic, you can now watch the video on-de­mand here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER